Get the newest information from the Immunization Program right in your inbox!
Sign up
Trouble logging in? Forgot password? We can help!
215-685-6784
215-238-6944
Complete the online reporting agreement form
Or fill out the
then email it to
vaxreporting@phila.gov
or fax to the contact above.
Complete in addition to the reporting agreement form to onboard more than 2 clinics.
Need help? Review the FAQ
Supply Updates and Borrowing VFC Doses The nirsevimab supply shortage continues to evolve and is not expected to resolve soon. Review this CDC advisory with updates about nirsevimab supply and recommendations to prioritize the use of the limited supply of this product. With these limitations, the Immunization Program wants...
Nirsevimab (Beyfortus) and COVID-19 Updates Nirsevimab Due to high demand and limited supply cited by the CDC, nirsevimab (Beyfortus) ordering through VFC has been put on hold as of October 17, 2023. The CDC is working with Sanofi to secure a supply of this immunization within the...
2023-2024 Novavax Now Available to Order Novavax COVID-19 vaccine, adjuvanted (2023-2024 formula) is now available to order. 2023-2024Novavax is authorized for individuals 12 years and older. This product package contains two multi dose vials each containing five doses. The NDC for this product is NDC # 80631-0105-02. It can...
Mpox Vaccine: Indigenous Peoples' Day Schedule The City of Philadelphia will be closed on Monday, October 9th in observance of Indigenous Peoples' Day. Mpox orders are due by 5pm on Tuesday, October 10th during this week. Deliveries will continue as normal. Order Mpox Vaccine ...
Beyfortus (nirsevimab) Now Available Through VFC On July 17, 2023, FDA licensed AstraZeneca and Sanofi’s Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD). On August 3, the ACIP voted unanimously to recommend nirsevimab for use in infants during the RSV...
COVID-19 Vaccine Commercialization Tuesday, September 12, 2023, marked the beginning of COVID-19 commercialization. Here are some important changes to be aware of in this new period of COVID-19 vaccination: The Department of Public Health’s COVID-19 program has formally ended. Bivalent COVID-19 vaccines are no longer authorized for...
Additional Vaccines Available for VFC Flumist and the Moderna 2023-24 COVID-19 vaccine for 6 mo – 11 yrs are now available to order for your VFC eligible patients through PhilaVax. FlumistEligibility: 2 - 18 yearsPackaging: 10 0.2 mL, intranasal sprayersCVX: 149CPT: 90672NDC: 66019-0310-10 View a step-by-step ordering guide. View more information...
VFC and VFAAR Shipping Delays Our vaccine distribution center is currently working through an unanticipated backlog of VFC and VFAAR orders as a result of having relocated. Due to this please be aware that there are likely to be delays with some vaccine shipments. For your September...
PIC Conference Registration Open Now! Philadelphia Immunization Coalition Fall Conference We are excited to invite you to join us for the 2023 Fall PIC Conference, at the College of Physicians in Philadelphia. Our speakers include Dr. Andrew Kroger and Dr. Paul Offit, among others to be announced....
COVID-19 Vaccine Available to Order Through VFC and the Bridge Access Program On September 12, 2023, ACIP approved the use of updated COVID-19 vaccines. The new products are monovalent (single), Omicron variant XBB.1.5. Under the new recommendation, everyone over 6 months is eligible for an updated...
Pediatric Pneumococcal Vaccine Updates As a reminder, Prevnar 20 (PCV20, Pneumococcal 20-valent Conjugant Vaccine; NDC 00005-2000-10) is now available to order for your VFC eligible patients. Prevnar 13 (PCV13) is no longer available to order through the VFC program. Please read our previous advisory on these changes. To transition...
COVID-19 Program Ends Today Today, Tuesday, September 12, 2023, marks the end of PDPH's COVID-19 program and the beginning of commercialization. Bivalent COVID-19 vaccines are no longer be authorized for use. Any remaining products in your inventory must be immediately discarded. Use of unauthorized product to vaccinate patients is not...
New Vaccine Product Available for VFC/VFAAR A one-vial presentation of Menveo (MenACYW-135) is now available through the Philadelphia VFC & VFAAR programs. This presentation does not require reconstitution. The Prescribing Information now describes both presentations of Menveo: the current two-vial presentation and a new one-vial presentation. One-vial Presentation (NEW) NDC: 58160-0827-30 For use in individuals 10 years through...
Urgent Update on COVID-19 Program The Philadelphia Department of Public Health's (PDPH) COVID-19 program is expected to end this Tuesday, 9/12 when full commercialization begins. Any COVID-19 vaccine in your inventory received from PDPH will no longer be authorized for use. All remaining inventory must be reported as wastage and...
Private COVID-19 Vaccine Procurement Commercialization of COVID-19 vaccines is occurring next week. VFC Providers are required to match vaccines on the private side. We have created an FAQ to assist providers through this transition. Take these steps now to plan which COVID-19 vaccines you will purchase privately: Review the anticipated...
[vc_row][vc_column][vc_column_text] New Vaccine Product Available Through VFC: Prevnar 20 On June 27, 2023, the CDC approved Prevnar 20 (PCV20) for use in pediatric patients. Beginning September 6, 2023, this Prevnar 20 is available to order for your VFC eligible patients. The Prevnar 13 (PCV13) is no longer...
Recap: RSV Immunization in Outpatient Settings Thank you to those who attended the RSV townhall for nirsevimab (Beyfortus) immunization in outpatient settings on Tuesday, August 29! In case you missed it, please review important information below: PDPH townhall presentation slides PDPH townhall meeting recording Nirsevimab FAQ Nirsevimab planning checklist Nirsevimab will...
Integrating RSV Immunization into EHR Systems RSV immunization will be available to order through the Vaccines for Children (VFC) program this fall. This newly approved monoclonal antibody, nirsevimab (Beyfortus), will be used to protect newborns and infants born during or entering their first RSV season.As your facility will likely...